Results With Mechanical Cardiac Valvular Prostheses
|
|
- Penelope Matthews
- 6 years ago
- Views:
Transcription
1 CURRENT REVEWS Results With Mechanical Cardiac Valvular Prostheses Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Mechanical cardiac valvular prostheses continue to be more popular than bioprostheses for heart valve replacement operations. Five different brands of mechanical heart valves are now approved for implantation in the United States: models 1260 and 6120,,,, and. Each model of mechanical valve has certain positive and negative attributes, but none is functionally mechanically perfect. A review of the published long- term results with these valves favors the and valves. A new method of assessing the thrombogenic potential and requirement for anticoagulation of the different mechanical valves, namely the composite thromboembolism and bleeding index, is proposed. Evaluation of the new index demonstrates a modest advantage for the valve, particularly in the aortic position. (Ann Thorac Surg 1995;60: ) D espite the increased aging of the valve replacement population in the United States and a trend toward insertion of more bioprostheses in these patients, mechanical heart valves continue to predominate over bioprostheses in the United States with an approximate 65 % to 35% market share advantage. Although the division of the valve market between mechanical and tissue valves varies widely among countries (for example, mechanical valves constitute approximately 90% of the market in Japan but only 10% of the market in Brazil), mechanical valves make up about 60% of the heart valves implanted worldwide. A report in 1991 reviewed the previous 15 years' experience from the English-language literature for the four mechanical cardiac valvular prostheses then approved by the Food and Drug Administration (FDA) for implantation in the United States [1]. Since that review, one more mechanical valve, the bileaflet prosthesis, was approved for market release by the FDA in This review updates the reported experience with the five mechanical valves currently approved by the FDA. The review is divided into three parts: first, an assessment of the functional mechanical characteristics of the prostheses; second, a review of the published complications; and third, a suggestion for an index that views in a new way the primary problem with mechanical valves, their inherent thrombogenicity, and requirement for anticoagulation. The Study Valves Table lists the five mechanical cardiac valvular prostheses currently approved by the FDA for implantation in the United States, their dates of introduction, the estimated number of each prosthesis inserted according to Address reprint requests to Dr Akins, Cardiac Surgical Unit, Massachusetts General Hospital White 503, 32 Fruit St, Boston, MA the individual manufacturer, and their current list prices in the United States. Photographs and a full description of the design characteristics of the models 1260 and 6120,,, and prostheses can be found in the review from 1991 [1]. The valve is a bileaflet prosthesis whose pyrolytic carbon-coated discs pivot inside a pyrolytic carbon housing. The Dacron sewing ring is carbon coated (Fig 1). The two leaflets open to 78 degrees from the horizontal axis, and the housing is rotatable within the sewing ring. Functional Mechanical Characteristics Table 2 lists a very subjective assessment of the functional mechanical performance of the five prostheses. The scale of numbers chosen is only intended to confer relative differences among the various valves and is not meant to have any other significance. The loss of structural integrity has only been reported for 2 model 6120 mitral valves in which silicone ball variance developed, and for approximately 15 to 20 valves. The Start-Edwards 1260 aortic prosthesis, the standard valve (the only model available in the United States), the valve, and the valve have not been reported to suffer loss of structural integrity in the clinical setting. The lowest profile is presented by the valve, followed closely by the prosthesis, whose pivot guards make it somewhat taller. Although the two single-disc valves have a low profile in the closed position, they do have a higher profile in the open position than do the bileaflet designs. The caged-ball design of the valves gives them the highest profile. Rotatability is not of any consequence for the Starr by The Society of Thoracic Surgeons /95/$9.50 SSD (95)
2 Ann Thorac Surg REVEW AKNS ;60: MECHANCAL VALVES Table 1. Mechanical Cardiac Valvular Prostheses Approved by the Food and Drug Administration Year Number List Valve Approved Design nserted Price 1965 Ball-cage 150,000 $4,300 (1260, 6120) 1977 Single tilting 170,000 $4,000 disc 1977 Bileaflet 600,000 $4, Single tilting 45,000 $3,800 disc 1993 Bileaflet 110,000 $4,250 Edwards caged-ball design. Of the four disc valves, only the prosthesis cannot be rotated within its sewing ring, which could be disadvantageous in some circumstances. A rotatable version of that prosthesis is reportedly being currently tested. Freedom from occluder impingement is poorest for the valve, because the occluder seats horizontally at the equator of the housing and thus can be immobilized by retained valve remnants or sutures that are left too long. Complete closure of the single disc and the discs of the two bileaflet valves can be hindered by subvalve structures, sutures, or native valve tissue as well, but the leaflets are uncommonly totally immobilized. Like the single disc of the valve, the discs of the valve seat closer to the edge of the housing and are, therefore, not as protected as those of the valve. mpingement of the ball of a valve, although uncommon, can occur if sutures or valve fragments fall across the metal housing and keep the ball from completely seating. The and valves have acceptably low and essentially equal transvalve gradients, even in small sizes. The gradient across a Carbo- Medics valve is minimally higher, probably due to the fact that the leaflets are designed not to open quite as far as those of the valve. n smaller sizes the valves have almost unacceptable gradients, and the has gradient relief characteristics that place it between the valves and the other disc prostheses. Complete opening of a mechanical valve can be viewed in two ways: first, the completeness of rotation or translation of the occluder from the closed to the open position; and second, the length of time that the occluder stays open during that portion of the cardiac cycle when it is intended to be open. Complete opening of the single disc of the valve is virtually always achieved both in terms of rotation and translation and also in terms of maintenance of the open position. n the aortic position both discs of the and the valves rotate to the open position uniformly and remain open during systole. However, one could argue that a perfect complete opening score is not justified for these two bileaflet valves because increasing evidence suggests that in the mitral position, when a bileaflet valve is implanted in the anatomic orientation, an important percent of those valves will demonstrate biphasic partial closure of both leaflets during diastole ("diastolic fluttering") in patients with atrial fibrillation [2, 3]. n an important number of cases the disc of the valve does not rotate to the open position completely [4, 5]. Although complete opening of the ball in a valve is the norm, ball rebound off the distal cage can affect the secondary orifice of the cagedball design, and also the inertia of the ball may keep it from completely opening or closing at high heart rates. Dynamic regurgitant fraction, that part of valvular regurgitation that occurs before the occluder becomes seated in the housing, is lowest in the single-disc prostheses, the and, followed closely by the bileaflet designs, the and. The minimally lower score for the bileaflet valves relates to the reported clinical frequency of asynchronous closure of the two discs in bileaflet valves [2, 3]. The inertia of a ball delays its closure. Static leak rate, that part of valvular regurgitation that occurs once the occluder is seated, is essentially nonexistent for the valves. The and valves have a moderate built-in leak rate to flush the disc and housing. The increased length of the lines of closure between the discs and the housing in conjunction with the tolerances needed to fulfill the engineered requirements for washing the valve components give the and valves somewhat higher static leak rates. Thus, each prosthetic design has some very strong mechanical advantages but also some important limitations. Review of Long-Term Complications To the reports used to prepare the previous review on this topic have been added those studies published Fig 1. cardiac valvular prosthesis.
3 1838 REVEW AKNS Ann Thorac Surg MECHANCAL VALVES 1995;60: Table 2. Mechanical Valve Functional Characteristics" Characteristic Structural integrity Profile Ability to rotate nterference with occluder Transvalve gradient Complete opening Dynamic regurgitant fraction Static leak rate ~ A grade of 5+ is the best and 0, the worst. through January The reports chosen had to use relatively standard definitions of valve-related complications [6], provide separate results for aortic and mitral prostheses, and contain enough information that the actual number of adverse events and the corresponding patient-years of follow-up could be accurately measured or closely approximated. As with the previous review, the statistical methods used in the available literature impose the use of linearized rates of complications; acknowledge the limitations of that method. There have been no new reports on the Start-Edwards valves. New sources of data were available for the [7-11 and my unpublished data], St. Jude Medical [12-20], and valves [21]. Data on the valve came from one large cumulative experience [22]. However, that multiinstitutional series reports only the linearized rates for "late" events. The author's contention was that because the FDA currently requires linearized rates for only those complications that occur more than 30 days after implantation and does not count any events that occur if the patient is never discharged postoperatively, reporting only "late" events is appropriate. Obviously the hazard function for most complications is highest in the early period after mechanical valve implantation and for prostheses with shorter periods of follow-up, "early" events will have a proportionally greater impact on the calculated linearized rates of complications. However, most reports about other prostheses include the "early" events, as suggested by the guidelines, and, therefore, the "early" events for the valve, which can be found in their company's published clinical update [231, have been included. The combined study populations for each type of prosthesis and the cumulative patient-years of follow-up are recorded in Table 3. The percentages in Table 3 demonstrate that we continue to have good long-term information on only a small sample of each valve type. As in the previous review [1], data are presented as a composite linearized rate for each complication, that is, the total number of all events from all applicable studies divided by the total patient-years of follow-up. The calculated rates from the previous study and the current report are both listed. Following each composite rate is the range of linearized rates reported, not the standard error of the mean. Each table also lists the number of patient-years of follow-up available to generate that particular composite linearized rate in addition to the range of 5- and 10-year actuarial event-free rates. Aortic Valves Nonstructural dysfunction, which comprises largely paravalvular leak and to a lesser extent hemolysis, is lowest in the aortic position (Table 4) for the Starr- Edwards valve, followed closely by the and valves. t is a little higher for the valve and further elevated for the valve. The incidence of thromboembolism in the aortic position (Table 5) is lowest for the valve, for which it has actually dropped between reports. Thromboembolism rate is a little higher and essentially currently equal for the,, and St. Jude Medical valves, while rising a bit between reports for the last prosthesis. The highest rate of thromboembolism is reported for the valve. n the case of the thrombosis subset of thromboembolism in the aortic position (Table 6) the valve has yet to have a reported case, and very low rates occur with the,, and St. Jude Medical valves. The incidence for the is minimally increased. The incidence of anticoagulant-related complications for aortic valves (Table 7) is reported to be the lowest now for the valve, but the number of patientyears of follow-up is very small. The rate of bleeding complications remains very low for the Table 3. Study Populations Number of Patient-Years Valve Valves Studied a of Follow-up 7,704 (5.1%) 37,479 4,479 (2.6%) 18,004 9,514 (1.6%) 36,676 1,174 (2.6%) 2,612 1,079 (1.0%) 2,656 a Numbers in parentheses are valves studied as a percentage of all valves of that model implanted.
4 ., Ann Thorac Surg REVEW AKNS ;60: MECHANCAL VALVES Table 4. Aortic Valve Replacement: Nonstn ctural Dysfunction Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 7, ( ) 7, (0-0.9) 1, ( ) 3, (0-3.4) 2, (0-3.4) 10, ( ) (0-6.7) (0.8) 1, Table 6. Aortic Valve Replacement: Thrombosis Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 15, ( ) 15, (0-1.1) 6, (0-1.1) 8, (0-0.7) 4, (0-0.3) 13, (0-0.8) (0-0.8) (0) 1, valve. The,, and Carbo- Medics have moderately elevated and very similar rates, with the rate for the valve having fallen between reports. The,, and valves have very similar low rates of prosthetic endocarditis in the aortic position (Table 8) with little change between reports. The rate reported for the valve is somewhat elevated. The rates of reoperation for aortic prostheses (Table 9) remain lowest for the valve and are minimally elevated for the,, and valves. The earlier higher rate for the valve has decreased during the interval between reports. Mitral Valves The incidence of nonstructural dysfunction in the mitral position (Table 10) is lowest for the valve and minimally elevated for the,, and prostheses. The rate for the valve is somewhat higher. Thromboembolism in the mitral position (Table 11) remains lowest and unchanged for the valve and somewhat higher for the valve. The rates for the and Table 5. Aortic Valve Replacement: Thromboembolism Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 19, ( ) 19, ( ) 6, ( ) 9, ( ) 6, ( ) 17, ( ) (0-5.1) (1.9) 1, Table 7. Aortic Valve Replacement: Anticoagulation Complications Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 19, ( ) 19, ( ) 5, ( ) 6, ( ) 5, (0-7.9) 14, (2.3) (0-2.3) (2,3) 1,553 Pby = patient-years O 73-95
5 1840 REVEW AKNS Ann Thorac Surg MECHANCAL VALVES 1995;60: Table 8. Aortic Valve Replacement: Prosthetic Valve Endocarditis Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 18, ( ) 18, (0-1.2) 5, ( ) 6, ( ) 4, ( ) 12, (0-1.9) (0-1.9) (0.4) 1, Table 10. Mitral Valve Replacement: Nonstructural Dysfunction Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 9, ( ) 9, ( ) 2, (0-2.1) 2, ( ) 1, (0-2.2) 12, ( ) (0-1.9) (1.4) 1, valves are increased a bit further, with the highest rates seen for the valve, for which prosthesis the incidence fell during the period between reports. The rate for the thrombosis subset in mitral valves (Table 12) remains very low for the,, and valves. Thrombosis rate in mitral valves is somewhat elevated, whereas the rate remains the highest for valves, even though the incidence has improved between reports. The incidence of anticoagulation-related complications for mitral valves (Table 13) remains lowest and unchanged for the valve and a little bit higher for the and valves. The rate is still higher for the valve and highest for the valve, having risen for that valve in the period between reports. Prosthetic endocarditis in mitral prostheses (Table 14) remains low in the,, and valves. The incidence is minimally higher for the valve and remains substantially elevated for the valve, despite an improvement between reports. Reoperation for mitral valves (Table 15) remains lowest for the valve and a little higher for the valve. The rates for the and valves are slightly higher and still con- Table 9. Aortic Valve Replacement: Reoperation Follow-up Valve and Year Rate (Range) (Pt-y) ( ) 19, ( ) 19, ( ) 1, ( ) 2, (0-0.9) 2, (0-1.4) 10, (2.4) (0-2.4) (0.6) 1, Table 11. Mitral Valve Replacement: Thromboembolism Rate Follow-up Valve and Year (Range) (Pt-y) Start-Edwards ( ) 18, ( ) 18, ( ) 6,63; ( ) 8, ( ) 5, ( ) 17, ( ) ( ) 1, (3.3) 1,
6 Ann Thorac Surg REVEW AKNS ;60: MECHANCAL VALVES Table 12. Mitral Valve Replacement: Thrombosis Valve and Year Rate (Range) Follow-up (Pt-y) (0-0.5) 9, (0-0.5) 9, (0-1.1) 4, (0-1.1) 5, (0-0.8) 3, ( ) 14, ( ) ( ) 1, (0.8) 1, Table 14. Mitra Valve Replacement: Prosthetic Valve Endocarditis Valve and Year Rate (Range) Follow-up (Pt-y) ( ) 16, ( ) 16, (0-1.7) 3, (0-1.7) 3, ( ) 3, (0-2.2) 14, (0-5.4) (0-5.4) (0.7) 1, siderably higher for the valve, even with an improvement in the interval between reports. Thromboembolism and Bleeding ndex The principal concern about mechanical valves remains their thrombogenic potential and the need for anticoagulation, essentially two sides of the same problem. ndeed, for each patient one might ask the question, at what cost of bleeding is one willing to seek no valve thrombosis and a low thromboembolic rate? The basis for this question is demonstrated in Figure 2, where one hopes that each patient can be managed to achieve his or Table 13. Mitral Valve Replacement: Anticoagulation Complications Rate Follow-up Valve and Year (Range) (Pt-y) ( ) 16, ( ) 16, ( ) 3, ( ) 3, ( ) 4, ( ) 16, (2.7) ( ) (2.2) 1, her anticoagulation at point X, namely, no thrombosis and the lowest level of thromboembolism for the lowest level of bleeding complications. Some reports in the literature, particularly before 1985, reported thromboembolic rates without reporting the corresponding rates of anticoagulant-related hemorrhage. Data from these reports would be counted in the composite rate for thromboembolism, but not for anticoagulant-related bleeding. Such reports might tend to distort the calculated rates. Thus, have generated a new measure of mechanical valve thrombogenicity, the "'composite thromboembolism and bleeding index," by selecting only those reports that provided accurate data for both thromboembolism and anticoagulant-related bleeding. The composite linearized rate in this index is calculated by adding together Table 15. Mitral Valve Replacement: Reoperation Valve and Year Rate (Range) Follow-up (Pt-y) ( ) 13, ( ) 13, ( ) 1, ( ) 2, ( ) 2, ( ) 14, (5.4) (0-5.4) (1.4) 1,
7 1842 REVEW AKNS Ann Thorac Surg MECHANCAL VALVES 1995;60: rr >. -" L n- O uj N n" 2 <: W Z i Embolism Thrombosis... Bleeding ~bolism, X~ss Bleeding s S # # Table 16. Aortic Valve Replacement: Thromboembolism and Bleeding ndex Valve Follow-up Patients (Pt-y) Rate (Range) References 4,024 19, ( ) [24-30] 1,450 6, ( ) [31-33p St. Jude Medical 3,861 14, ( ) [3, 13, 15-19, 30, 34-38] (0-7.14) [21, 39] 603 1, (4.25) [22, 23] '~ ncludes my own unpublished data.. rombosis o 6 o NTERNATONAL NORMALZED RATO (NR) Fig 2. Relationship of level of anticoagulation to the incidences of thrombosis, thromboembolism, and bleeding for a hypothetical patient with a mechanical heart valve. X marks the ideal point of no thrombosis and the fewest thromboembolic events for the lowest level of anticoagulant-related bleeding. all thromboembolic and bleeding events from those reports that provide both numbers and dividing by the cumulative patient-years of follow-up from those reports. Studies that report data for only one of the complications are excluded. Further, in keeping with the previous design, the results for aortic and mitral valves have been separated. The composite thromboembolism and bleeding indices for aortic prostheses are recorded in Table 16, along with the total number of patients and patient-years of follow-up available to generate that number for each model of valve. The lowest composite index for aortic valves is reported for the valve, but this number is generated from data available for only 81 patients and 139 patient-years of follow-up. For the other valves for which there is much better follow-up, the lowest index is reported for the valve at 2.77% per patient-year. The rate for the valve is considerably higher, followed by almost identical rates for the bileaflet and valves. Table 17 contains the composite thromboembolism and bleeding rates for mitral valves. The lowest incidence is reported for the valve, followed closely by the prosthesis. The and valves have moderately higher rates, with a much increased rate for the valve, albeit again with a limited number of patients. Whether this new index proves to be of value to surgeons in choosing among various valves remains to be seen. One would hope that at the very least all future reports on the long-term results with mechanical valves would clearly provide information about both thromboembolic and bleeding complications. Comment The findings in this review are generally similar to those reported in Although the models 1260 and 6120 valves have demonstrated noteworthy durability, their poorer gradient relief and somewhat elevated incidence of valve-related complications make them not truly competitive with current disc prostheses. Results reported with the valve, although widely disparate, do not favor its hemodynamic performance or its freedom from complications. The and, to a lesser extent, the valves continue to be the most popular mechanical prostheses in the United States because of their clinically documented excellent and comparable hemodynamic performance in addition to their acceptably low rates of valve-related complications. f there are any differences between the long-term performance of Table 17. Mitral Valve Replacement: Thromboembolism and Bleeding ndex Follow-up Rate Valve Patients (Pt-y) (Range) References 3,242 16, ( ) [27, 28, 40, 41] 1,083 3, ( ) [9, 31-33, 42] "~ St. Jude Medical 3,850 16, ( ) [3, 9, 13-19, 35-38, 43] ( ) [21, 42] 476 1, (4.99) [22, 23] " ncludes my own unpublished data.
8 Ann Thorac Surg REVEW AKNS ;60: MECHANCAL VALVES these two prostheses, it may be that the valve may have a modest advantage in terms of diminished thrombogenicity, whereas the valve has a lower reported rate of reoperation. The major potential drawback of the valve remains its reported loss of structural integrity in occasional patients, albeit a very low percentage, whereas the primary shortcoming of the valve is still the attention required of the surgeon at the time of insertion to avoid occluder impingement. Finally the valve, the new addition to the list, probably fits into the ranking just behind the and valves on the basis of somewhat higher transvalve gradients and increased incidence of thromboembolism despite adequate anticoagulation, especially in the mitral position. Longer follow-up will be necessary to accurately determine whether the valve or the valve will become truly competitive with the Medtronic- Hall and valves. This report does not provide any determinations of statistical significance comparing the results with different prostheses. Any retrospective, cumulative study such as this is potentially subject to major problems with statistical reliability. The numbers generated for the reported complications for each prosthesis are clearly dependent on the validity of the individual studies, which were often performed according to different protocols. n addition the characteristics of the different patient populations that constitute the various study groups are obviously widely disparate. have, therefore, never felt comfortable applying univariate statistical methods to this multivariate problem, namely, comparing the differences between observed results with different prostheses from differing populations, collected by various methods. One particular difficulty uncovered in this review warrants some emphasis and demonstrates how results with the same valve used in different institutions can produce conflicting results. Recent reports of results with the St. Jude Medical valve from Japan and Germany, two highly developed countries with well-organized health care systems, are examples of this apparent anomaly. Beginning with aortic prostheses, Aoyagi and colleagues [18] in Kurume, Japan, report the linearized rates for thromboembolism, anticoagulantrelated bleeding, and the composite thromboembolism and bleeding index to be 1.0%, 0.4%, and 1.3% per patient-year, respectively. Similarly, Nakano and associates [17] from Tokyo, Japan, report the linearized rates for thromboembolism, anticoagulant-related bleeding, and the composite thromboembolism and bleeding index for aortic valves to be 1.4%, 0.1%, and 1.5% per patient-year, respectively. n contrast Horstkotte and co-workers [16] from Dusseldorf, Germany, report for their aortic prostheses the linearized rates of thromboembolism, anticoagulant-related bleeding, and the composite thromboembolism and bleeding index to be 2.7%, 4.1%, and 6.8% per patient-year, respectively. n addition the German data do not contain events that occurred within the first 3 months after valve implantation, nor do they contain more than the first event for patients who suffered multiple events! For mitral valves Aoyagi and colleagues [18] report the linearized rates of thromboembolism, anticoagulant-related bleeding, and the composite thromboembolism and bleeding index to be 1.0%, 0.3%, and 1.2% per patient-year, respectively. Also, Nakano and associates [17] report their linearized rates for thromboembolism, anticoagulant-related bleeding, and the composite thromboembolism and bleeding index for mitral valves to be 1.7%, 0.2%, and 1.9% per patient-year, respectively. However, the German report [16] yields greatly different results for mitral prostheses with the linearized rates for thromboembolism, anticoagulantrelated bleeding, and the composite thromboembolism and bleeding index being 4.4%, 6.4%, and 10.8% per patient-year, respectively, with early and multiple events again excluded. How is one to account for this extraordinary variability in results with the same prosthesis used in different high-quality health care systems? There is no clear answer. We have learned certain lessons about reporting results with mechanical heart valves over the years. First, the more frequently one interviews patients, the greater will be the number of incidents remembered by the patients, and thus the higher the incidence of complications. Second, the thromboembolic and bleeding complications recorded in any study may be important functions of the individual prosthesis, but they are probably also functions of other variables, for example, patient age, diet, inherent hematologic function, type of valvular disease, the capabilities of the person managing the patient's anticoagulation, or the intensity with which the information about complications is sought. One other issue raised by this review is the efficacy of the previously published guidelines for reporting morbidity and mortality after cardiac valvular procedures [6]. The impact of other variables, especially patient factors, on the complications attributed to mechanical prostheses is becoming increasingly clear. We may be at a time when the previous guidelines need to be revised to achieve a more thorough assessment of the impact of other risk factors on the complications ascribed to mechanical cardiac valvular prostheses. f a review such as this has any usefulness, it is that first, it brings together information from many studies to increase the sample size for each prosthesis; second, it may serve as a standard against which one may compare future results; third, it may serve as a stimulus for other cardiac surgical groups to investigate and report their results; and finally, it may encourage us to reassess the methods we use to evaluate mechanical valves. References 1. Akins CW. Mechanical cardiac valvular prostheses. Ann Thorac Surg 1991;52: Feldman HJ, Gray RJ, Chaux A, et al. Noninvasive in vivo and in vitro study of the St. Jude mitral valve prosthesis. Am J Cardiol 1982;48:
9 1844 REVEW AKNS Ann Thorac Surg MECHANCAL VALVES 1995;60: Panidis P, Ren JF, Kotler MN, et al. Clinical and echocardiographic evaluation of the St. Jude cardiac valve prosthesis: follow-up of 126 patients. J Am Coll Cardiol 1984;4: Carrier M, Martineau JP, Bonan R, Pelletier LC. Clinical and hemodynamic assessment of the prosthetic heart valve. J Thorac Cardiovasc Surg 1987;93: Kazui T, Komatsu S, noue N. Clinical evaluation of the aortic disc valve prosthesis. Scand J Thorac Cardiovasc Surg 1987;21: Edmunds LH Jr, Clark RE, Cohn LH, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg 1988;46: Vallejo JL, Gonzalez-Santos JM, Albertos J, et al. Eight years' experience with the valve prosthesis. Ann Thorac Surg 1990;50: Keenan RJ, Armitage JM, Trento A, et al. Clinical experience with the vane prosthesis. Ann Thorac Surg 1990;50: Fiore AC, Naunheim KS, D'Orazio S, et al. Mitral valve replacement: randomized trial of St. Jude and Medtronic- Hall prostheses. Ann Thorac Surg 1992;54: R~bago G, Corbi P, Tedy G, et al. Five-year experience with the Medtronic Hall prosthesis in isolated aortic valve replacement. J Cardiac Surg 1993;8: Kim Y, Lesaffre E, Scheys, Stalpaert G, Flameng WJ, Daenen WJ. The Monostrut versus Medtronic Hall prosthesis: a prospective randomized study. J Heart Valve Dis 1994;3: Burckhardt D, Striebel D, Vogt S, et al. Heart valve replacement with valve prosthesis: long-term experience in 743 patients in Switzerland. Circulation 1988; 78(Suppl 1): Kratz JM, Crawford FA Jr, Sade RM, Crumbley AJ, Stroud MR. St. Jude prosthesis for aortic and mitral valve replacement: a ten-year experience. Ann Thorac Surg 1993;56: Jegaden O, Eker A, Delahaye F, et al. Thromboembolic risk and late survival after mitral valve replacement with the St. Jude Medical valve. Ann Thorac Surg 1994;58: Khan S, Chaux A, Matloff J, et al. The valve: experience with 1000 cases. J Thorac Cardiovasc Surg 1994; 108: Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity anticoagulation therapy results in lower complication rates with the prosthesis. J Thorac Cardiovasc Surg 1994;107: Nakano K, Koyanagi H, Hashimoto A, et al. Twelve years' experience with the valve prosthesis. Ann Thorac Surg 1994;57: Aoyagi S, Oryoji A, Nishi Y, Tanaka K, Kosuga K, Oishi K. Long-term results of valve replacement with the St. Jude Medical valve. J Thorac Cardiovasc Surg 1994;108: brahim M, O'Kane H, Cleland J, Gladstone D, Sarsam M, Patterson C. The prosthesis: a thirteen-year experience. J Thorac Cardiovasc Surg 1994;108: Fernandez J, Laub GW, Adkins MS, et al. Early and latephase events after valve replacement with the St. Jude Medical prosthesis in 1200 patients. J Thorac Cardiovasc Surg 1994;107: Akalin H, ~orap~io~lu ET, Ozyurda U, et al. Clinical evaluation of the cardiac valve prosthesis: follow-up of up to 6 years. J Thorac Cardiovasc Surg 1992;103: Copeland JG ll. An international experience with the prosthetic heart valve. J Heart Valve Dis 1995;4: Burnett C. The clinical report. 1995;7: Miller DC, Oyer PE, Mitchell RS, et al. Performance characteristics of the model 1260 aortic valve pros- thesis beyond ten years. J Thorac Cardiovasc Surg 1984;88: Perier P, Bessou JP, Swanson JS, et al. Comparative evaluation of aortic valve replacement with Starr, Bj6rk, and porcine valve prostheses. Circulation 1985;72(Suppl 2): Hackett D, Fessatidis, Sapsford R, Oakley C. Ten year clinical evaluation of 2400 and 1260 aortic valve prostheses. Br Heart J 1987;57: Corcos T, Gandjbakhch, Parle A, et al. Long-term results of valve replacement with the silicone ball prostheses [Abstract]. Circulation 1987;76(Suppl 4): Akins CW, Buckley MJ, Daggett WM, Austen WG, Hilgenberg AD, Jacobs ML. Ten-year follow-up of the Starr- Edwards prosthesis. n: Rabago G, Cooley DA, eds. Heart valve replacement and future trends in cardiac surgery. Mt. Kisco, NY: Futura, 1987: Cobanoglu A, Fessler CL, Guvendik L, Grunkemeier G, Starr A. Aortic valve replacement with the Start-Edwards prosthesis: a comparison of the first and second decades of follow-up. Ann Thorac Surg 1988;45: Lund O, Knudsen MA, Pilegaard H<, Magnussen K, Nielsen TT. Long-term performance of the Silastic ball valves and St Jude Medical bi-leaflet valves. Eur Heart J 1990;11: Beaudet RL, Nakhle G, Beaulieu CR, Doyle D, Gauvin C, Poirier NL. prosthesis: valve related deaths and complications. Can J Cardiol 1988;4: Nitter-Hauge S, Abdelnoor M. Ten-year experience with the Medtronic Hall valvular prosthesis. Circulation 1989; 80(Suppl 1): Antunes MJ, Wessels A, Sadowski RG, et al. Medtronic Hall valve replacement in a third-world population group. A review of the performance of 1000 prostheses. J Thorac Cardiovasc Surg 1988;95: Douglas PS, Hirshfeld JW Jr, Edie RN, Harken AH, Stephenson LW, Edmunds LH Jr. Clinical comparison of St. Jude and porcine aortic valve prostheses. Circulation 1985;72(Suppl 2): Arom KV, Nicoloff DM, Kersten TE, Lindsay WG, Northrup WF l. prosthesis: valve-related deaths and complications. Ann Thorac Surg 1987;43: DiSesa VJ, Collins JJ Jr, Cohn LH. Hematological complications with the St. Jude valve and reduced-dose Coumadin. Ann Thorac Surg 1989;48: Duncan JM, Cooley DA, Reul GJ, et al. Durability and low thrombogenicity of the valve at 5-year follow-up. Ann Thorac Surg 1986;42: Kinsley RH, Antunes MJ, Colsen PR. valve replacement. J Thorac Cardiovasc Surg 1986;92: R;ibago G, Martinell J, Fraile J, Andrade G, Montenegro R. Results and complications with the prosthesis. J Thorac Cardiovasc Surg 1984;87: Miller DC, Oyer PE, Stinson, EB, et al. Ten to fifteen year reassessment of the performance characteristics of the Start- Edwards model 6120 mitral valve prosthesis. J Thorac Cardiovasc Surg 1983;85: Schoevaerdts JC, Buche M, El Geriani A, et al. Twenty years' experience with the model 6120 valve in the mitral position. J Thorac Cardiovasc Surg 1987;94: Cortina JM, Martinell J, Artiz V, Fraile J, R~ibago G. Comparative clinical results with the (STM1), and Bj6rk-Shiley convexo-concave (70 ) prostheses in mitral valve replacement. J Thorac Cardiovasc Surg 1986;91: Douglas PS, Hirshfeld JW Jr, Edie RN, Stephenson LW, Gleason K, Edmunds LH Jr. Clinical comparison of St. Jude and porcine mitral valve prostheses. J Cardiovasc Surg (Torino) 1988;29:
Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationLong-Term Results With the Medtronic-Hall Valvular Prosthesis
Long-Term Results With the Medtronic-Hall Valvular Prosthesis Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Background. Although more than 170,000 Medtronic-
More informationThe CarboMedics bileaflet prosthetic heart was introduced
The CarboMedics Valve: Experience With 1,049 Implants José M. Bernal, MD, José M. Rabasa, MD, Francisco Gutierrez-Garcia, MD, Carlos Morales, MD, J. Francisco Nistal, MD, and José M. Revuelta, MD Department
More informationA valve was initiated at the Medical University of
St. Jude Prosthesis for Aortic and Mitral Valve Replacement: A Ten-Year Experience John M. Kratz, MD, Fred A. Crawford, Jr, MD, Robert M. Sade, MD, Arthur J. Crumbley, MD, and Martha R. Stroud, MS Division
More informationP have been used for mitral and aortic valve replacement
A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani,
More informationMultiple mechanical valve replacement surgery comparison of St. Jude Medical and CarboMedics prostheses
European Journal of Cardio-thoracic Surgery 13 (1998) 151 159 Multiple mechanical valve replacement surgery comparison of St. Jude Medical and CarboMedics prostheses W.R. Eric Jamieson *, A. Ian Munro,
More informationLong-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
J Korean Med Sci 2007; 22: 1060-4 ISSN 1011-8934 DOI: 10.3346/jkms.2007.22.6.1060 Copyright The Korean Academy of Medical Sciences Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
More informationPrognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards
European Heart Journal Supplements (1) 3 (Supplement Q), Q27 Q32 Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding
More informationTwenty-year experience with the St Jude Medical mechanical valve prosthesis
Surgery for Acquired Cardiovascular Disease Ikonomidis et al Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S. Ikonomidis, MD, PhD John M. Kratz, MD Arthur J. Crumbley
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationOn October 3, 1977, the first St. Jude Medical (SJM)
The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Robert W. Emery, MD, Christopher C. Krogh, Kit V. Arom, MD, PhD, Ann M. Emery, RN, Kathy Benyo-Albrecht,
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationHeart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients
European Heart Journal (1990) 11, 583-591 Heart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients S. VOGT, A. HOFFMANN, J. ROTH, P. DUBACH,
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationEvaluation of St. Jude Medical Valve s Long-term Function by Doppler Echocardiography
Evaluation of St. Jude Medical Valve s Long-term Function by Doppler Echocardiography Akira Sezai, MD, Motomi Shiono, MD, Kenji Akiyama, MD, Yukihiko Orime, MD, Hiroaki Hata, MD, Shinya Yagi, MD, Tomonori
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationThe St. Jude Medical mechanical valve is a low-profile,
Twenty-Five Year Experience With the St. Jude Medical Mechanical Valve Prosthesis J. Matthew Toole, MD, Martha R. Stroud, MS, John M. Kratz, MD, Arthur J. Crumbley III, MD, Scott M. Bradley, MD, Fred A.
More informationThe St. Jude Valve Prosthesis: Analysis of the Clinical Results in 815 Implants and the Need for Systemic Anticoagulation
JACC Vol. 13. No. I 57 Jxuary IYX9:57-h? The St. Jude Valve Prosthesis: Analysis of the Clinical Results in 815 Implants and the Need for Systemic Anticoagulation MARY LEE MYERS, MD, FACC, GERALD M. LAWRIE,
More informationSangho Rhie, M.D.*, Jun Young Choi, M.D.*, In Seok Jang, M.D.*, Jong Woo Kim, M.D.*, Chung Eun Lee, M.D.*, Hyun Oh Park, M.D.*
Korean J Thorac Cardiovasc Surg 2011;44:220-224 ISSN: 2233-601X (Print) ISSN: 2093-6516 (Online) Clinical Research DOI:10.5090/kjtcs.2011.44.3.220 Relationship between the Occurrence of Thromboembolism
More information40 Years Experience in Mitral Valve Replacement Using Starr-Edwards, St. Jude Medical and ATS Valves
Original Article 40 Experience in Mitral Valve Replacement Using Starr-Edwards, St. Jude Medical and ATS Valves Akira Sezai, MD, Motomi Shiono, MD, Mitsumasa Hata, MD, Mitsuru Iida, MD, Masataka Yoda,
More informationDurability of Pericardial Versus Porcine Aortic Valves
Journal of the American College of Cardiology Vol. 44, No. 2, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.01.053
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationClinical validation of a new drug seeking Food and
THE STATISTICIAN S PAGE Prosthetic Heart Valves: Objective Performance Criteria Versus Randomized Clinical Trial Gary L. Grunkemeier, PhD, Ruyun Jin, MD, and Albert Starr, MD Providence Health System,
More informationSurgery for Acquired Cardiovascular Disease
Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after mitral valve replacement W. R. E. Jamieson, MD, O. von Lipinski, MD, R. T.
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4)
European Heart Journal Supplements (2001) 3 (Supplement Q), Q33 Q38 Intensity of oral anticoagulation after implantation of St. Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4)
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationON-X and St.Jude Medical mechanical prosthesis. A paradox concept: they are equal but different
Accepted Manuscript ON-X and St.Jude Medical mechanical prosthesis. A paradox concept: they are equal but different Francesco Formica, MD, Stefano D Alessandro, MD, FECTS, Umberto Benedetto PII: S0022-5223(19)30709-3
More informationLONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP
LONG-TERM RESULTS OF HEART VALVE REPLACEMENT WITH THE EDWARDS DUROMEDICS BILEAFLET PROSTHESIS: A PROSPECTIVE TEN-YEAR CLINICAL FOLLOW-UP Bruno K. Podesser, MD a Gudrun Khuenl-Brady, MD a Ernst Eigenbauer,
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationClinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years
Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years John B. Chambers, MD, FRCP, FACC, a Jose L. Pomar, MD, PhD, FETCS, b Carlos A. Mestres,
More informationThe Medtronic-Hall Cardiac Valve:
The Medtronic-Hall Cardiac Valve: 7?h Years' Clinical Experience Regent L. Beaudet, M.D., Normand L. Poirier, M.D., Daniel Doyle, M.D., Gisde Nakhlb, M.Sc., and Christiane Gauvin, M.T. ABSTRACT Clinical
More information164 Ann Thorac Surg 45: , Feb Copyright by The Society of Thoracic Surgeons
Heart Valve Replacement with the Bjork-Shiley Mbnostrut Valve: Early Results of a Multicenter Clinical Investigation Lars I. Thulin, M.D., William H. Bain, F.R.C.S., Hans H. Huysmans, M.D., Gerrit van
More informationThe St. Jude Medical valve
Surgery for Acquired Heart Disease The St. Jude Medical valve Experience with 1 cases We analyzed the long-term results of valve replacement with the St. Jude Medical bileaflet valve (St. Jude Medical,
More informationVALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED?
VALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED? Eugene A. Grossi, MD Aubrey C. Galloway, MD Jeffrey S. Miller, MD Greg H. Ribakove, MD Alfred T. Culliford,
More informationEVERYTHING ABOUT MECHANICAL VALVES HAS CHANGED
EVERYTHING ABOUT MECHANICAL VALVES HAS CHANGED 106180.001 CryoLife - New Brochure FIN.indd 1 06/10/2016 14:08 Why use another mechanical valve when 1 2 3 No other mechanical valve has: 1 90 leaflets: 1
More informationAortic valve replacement in predominant aortic stenosis: What is an appropriate size valve?
IJTCVS Joshi et al 141 Aortic valve replacement in predominant aortic stenosis: What is an appropriate size valve? Kishore Joshi, M.Ch., Sachin Talwar, M.Ch., Devagourou Velayoudham, M.Ch., Arkalgud Sampath
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationEcho Evaluation of a Mitral Valve Prostheses Sunday, February 14, :50 2:10 PM 20 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ Echo Evaluation of a Mitral Valve Prostheses Sunday, February 14, 2016 1:50 2:10 PM 20 min 1 M U H A M E D S A R I Ć, M D, P H D D i r e c t
More informationSince Hufnagel and associates implanted a plastic ball
Evaluation of Valve Sound and Its Effects on ATS Prosthetic Valves in Patients Quality of Life Akira Sezai, MD, Motomi Shiono, MD, Yukihiko Orime, MD, Hiroaki Hata, MD, Shinya Yagi, MD, Nanao Negishi,
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationRepeated Thromboembolic and Bleeding Events After Mechanical Aortic Valve Replacement
Repeated Thromboembolic and Bleeding Events After Mechanical Aortic Valve Replacement Filip P. Casselman, MD, Michiel L. Bots, MD, PhD, Willem Van Lommel, MD, Paul J. Knaepen, MD, Ruud Lensen, MD, PhD
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationSt. Jude Medical and CarboMedics Mechanical Heart Valves in the Aortic Position
Clinical Investigation Ozer Kandemir, MD Hilmi Tokmakoglu, MD Ulku Yildiz, MD Tevfik Tezcaner, MD A. Cem Yorgancioglu, MD Ilhan Gunay, MD Kaya Suzer, MD Yaman Zorlutuna, MD St. Jude Medical and CarboMedics
More informationCARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP
CARPENTIER-EDWARDS PERICARDIAL VALVES IN THE MITRAL POSITION: TEN-YEAR FOLLOW-UP M. R. Aupart, MD P. H. Neville, MD S. Hammami, MD A. L. Sirineili, MD Y. A. Meurisse, MD M. A. Marchand, MD Objective: The
More informationby Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D., L. H. Burr, M.D., R. T. Miyagishima, M.D.
Carpentier-Edwards Standard Porcine Bioprosthesis: Primary Tissue Failure (Structural Valve Deterioration) by Age Groups W. R. E. Jamieson, M.D., L. J. Rosado, M.D., A. I. Munro, M.D., A. N. Gerein, M.D.,
More informationLONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS
LONG-TERM OUTCOME AFTER BIOLOGIC VERSUS MECHANICAL AORTIC VALVE REPLACEMENT IN 841 PATIENTS David S. Peterseim, MD Ye-Ying Cen, MA Srinivas Cheruvu, MHS Kevin Landolfo, MD Thomas M. Bashore, MD James E.
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More informationSmeloff-Cutter Prosthesis: 1- to 12-Year Follow-up David S. Starr, M.D., Gerald M. Lawrie, M.D., J. F. Howell, M.D., and George C. Morris, Jr., M.D.
Clinical Experience with the Smeloff-Cutter Prosthesis: 1- to 12-Year Follow-up David S. Starr, M.D., Gerald M. Lawrie, M.D., J. F. Howell, M.D., and George C. Morris, Jr., M.D. ABSTRACT To determine the
More informationBall Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation
Ball Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation Begonia Gometza, MD, and Carlos M. G. Duran, MD, PhD Department of Cardiovascular Diseases, King Faisal Specialist Hospital
More informationThe Optimal Intensity of Vitamin K Antagonists in Patients With Mechanical Heart Valves Meta-Analysis
Journal of the American College of Cardiology Vol. 42, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2003.07.029
More informationControversy exists regarding which valve type is best
Treatment of Endocarditis With Valve Replacement: The Question of Tissue Versus Mechanical Prosthesis Marc R. Moon, MD, D. Craig Miller, MD, Kathleen A. Moore, BS, Phillip E. Oyer, MD, PhD, R. Scott Mitchell,
More informationAortic Valve Replacement with Starr-Edwards Valves over 14 Years
Aortic Valve Replacement with Starr-Edwards Valves over 4 Years W. H. Wain, B.Sc., Ph.D., P. J. Drury, B.Sc., Ph.D., andd. N. Ross, F.R.C.S. ABSTRACT Three hundred thirteen patients underwent aortic valve
More informationSREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM, KERALA, INDIA
SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM, KERALA, INDIA - 695011 St. Jude Medical versus TTK Chitra mechanical heart valves at aortic/mitral postion Comparison
More informationPrimary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: Hancock I Vekus Carpentier-Edwards at 4- to 7-Years Follow-up
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: A Hancock I Vekus Edwards at 4- to 7-Years Follow-up Francisco Nistal, M.D., Edurne Artifiano, M.D., and Ignacio Gallo,
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationThe Starr-Edwards Valve
lacc Vol. 6, No.4 899 The Starr-Edwards Valve ALBERT STARR, MD, FACC Portland, Oregon This report reviews the results obtained with the current models of the Silastic ball valve, classifying the experience
More informationFrom the Editor Robert More Vice President Research and Development Medical Carbon Research Institute (MCRI)
The On-X Experience Medical Carbon Research Institute, LLC September 2000/Volume 2/Issue 1 From the Editor Robert More Vice President Research and Development Medical Carbon Research Institute (MCRI) This
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationFavorable Results in Patients with Small Size CarboMedics Heart Valves in the Aortic Position
Favorable Results in Patients with Small Size CarboMedics Heart Valves in the Aortic Position Kazuhito Imanaka, MD, Shinichi Takamoto, MD, and Akira Furuse, MD 2 Hemodynamic performance of the CarboMedics
More informationThe operative mortality associated with repeat heart valve surgery is. Repeat heart valve surgery: Risk factors for operative mortality
Surgery for Acquired Cardiovascular Disease Repeat heart valve surgery: Risk factors for operative mortality J. Mark Jones, MA, AFRCS a Hugh O Kane, MCh, FRCS a Dennis J. Gladstone, FRCS a Mazin A. I.
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationThe Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients
The Last Generation of Pericardial Valves in the Aortic Position: Ten-Year Follow-up in 589 Patients Michel R. Aupart, MD, Agnes L. Sirinelli, MD, Frank F. Diemont, MD, Yvon A. Meurisse, MD, Xavier B.
More informationThe pulmonary valve is the most common heart valve
Biologic versus Mechanical Valve Replacement of the Pulmonary Valve After Multiple Reconstructions of the RVOT Tract S. Adil Husain, MD, and John Brown, MD Indiana University School of Medicine, Department
More informationThe diameter of the aortic valve is in direct proportion
The CarboMedics Top-Hat Supraannular Prosthesis José M. Bernal, MD, Rafael Martin-Duran, MD, José M. Rabasa, MD, and José M. Revuelta, MD Departments of Cardiovascular Surgery and Echocardiography, Hospital
More information25 different brand names >44 different models Sizes mm
Types of Prosthetic Valves BIOLOGIC STENTED Porcine xenograft Pericardial xenograft STENTLESS Porcine xenograft Pericardial xenograft Homograft (allograft) Autograft PERCUTANEOUS MECHANICAL Bileaflet Single
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationMitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients
Mitroflow Synergy Prostheses for Aortic Valve Replacement: 19 Years Experience With 1,516 Patients Kazutomo Minami, MD, Armin Zittermann, PhD, Sebastian Schulte-Eistrup, MD, Heinrich Koertke, MD, and Reiner
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationP substitutes since the introduction of the Ionescu-
Mitroflow Pericardial Valve: Long-Term Durability Daniel Y. Loisance, MD, Jean-Philippe Mazzucotelli, MD, Patrick C. Bertrand, MD, Philippe H. Deleuze, MD, and Jean-Paul Cachera, MD Department of Surgical
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationThe CarboMedics prosthetic valve (Sulzer CarboMedics,
Long-Term Result of 1144 CarboMedics Mechanical Valve Implantations Chang Hyun Kang, MD, Hyuk Ahn, MD, Kyung Hwan Kim, MD, and Ki-Bong Kim, MD Department of Thoracic and Cardiovascular Surgery, Seoul National
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationRepeated mitral valve replacement in a patient with extensive annular calcification
CASE REPORT Open Access Repeated mitral valve replacement in a patient with extensive annular calcification Tadashi Kitamura 1,2*, Sachito Fukuda 1, Takahiro Sawada 1, Sumio Miura 1, Ikutaro Kigawa 1,3
More informationAspirin or Coumadin as the Drug of Choice
Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis L. Nufiez, M.D., M. Gil Aguado, M.D., D. Celemin, M.D., A. Iglesias, M.D., and J. L. Larrea, M.D. ABSTRACT Eight
More informationAssessment of Hemodynamics Properties of a New-Type Artificial Heart Valve Prosthesis Using Catheterization and Echocardiography
American Journal of Hematology 81:563 567 (2006) Assessment of Hemodynamics Properties of a New-Type Artificial Heart Valve Prosthesis Using Catheterization and Echocardiography Y.J. Zeng, 1,4 * S.W. Xu,
More informationBiological or mechanical valve prosthesis?
XXIX Giornate Cardiologiche Torinesi ADVANCES IN CARDIAC ARRHYTHMIAS AND GREAT INNOVATIONS IN CARDIOLOGY Turin, October 27-28, 2017 Centro Congressi Unione Industriale WHAT HAS CHANGED IN CARDIAC SURGERY?
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationPorcine bioprosthesis use for surgical treatment of
Fifteen-Year Clinical Experience With the Biocor Porcine Bioprostheses in the Mitral Position Kaan Kırali, MD, Mustafa Güler, MD, Altuğ Tuncer, MD, Bahadır Dağlar, MD, Gökhan İpek, MD, Ömer Işık, MD, and
More informationCarpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years
Surgery for Acquired Cardiovascular Disease Carpentier-Edwards supra-annular aortic porcine bioprosthesis: Clinical performance over 20 years W. R. Eric Jamieson, MD, Lawrence H. Burr, MD, Robert T. Miyagishima,
More informationHemodynamics and Early Clinical Performance of the St. Jude Medical Regent Mechanical Aortic Valve
Hemodynamics and Early Clinical Performance of the St. Jude Medical Regent Mechanical Aortic Valve David S. Bach, MD, Marc P. Sakwa, MD, Martin Goldbach, MD, Michael R. Petracek, MD, Robert W. Emery, MD,
More informationNearly 40 years after the pioneering efforts of Starr and
Prognosis After Aortic Valve Replacement With a Bioprosthesis Predictions Based on Meta-Analysis and Microsimulation J.P.A. Puvimanasinghe, MBBS, MSc, MD; E.W. Steyerberg, PhD; J.J.M. Takkenberg, MD; M.J.C.
More informationThe ATS Medical Open Pivot heart valve (ATS Medical, 10-Year Experience With the ATS Mechanical Valve in the Mitral Position
10-Year Experience With the ATS Mechanical Valve in the Mitral Position Constantin Stefanidis, MD, Albert M. Nana, MD, Didier De Cannière, MD, PhD, Martine Antoine, MD, Jean-Luc Jansens, MD, Chi-Hoang
More informationThe risk-benefit ratio of mitral valve operation is
Degenerative Mitral Regurgitation: When Should We Operate? Malcolm J. R. Dalrymple-Hay, PhD, Mark Bryant, Richard A. Jones, MRCP, Stephen M. Langley, FRCS, Steven A. Livesey, FRCS, and James L. Monro,
More informationInfluence of Prosthetic Heart Valve Sound on a Patient s Quality of Life
Original Article Influence of Prosthetic Heart Valve Sound on a Patient s Quality of Life Katsuo Nishi, MD, 1 Kiyoyuki Eishi, MD, 2 Yoshisada Shibata, PhD, 3 Jun Amano, MD, PhD, 4 Tatsuo Kaneko, MD, 5
More informationRead at the Twenty-fourth Annual Meeting of The Western Thoracic Surgical Association, Whistler, British Columbia, June 24-27, 1998.
STRUCTURAL VALVE DETERIORATION IN MITRAL REPLACEMENT SURGERY: COMPARISON OF CARPENTIER-EDWARDS SUPRA-ANNULAR PORCINE AND PERIMOUNT PERICARDIAL BIOPROSTHESES W. R. Eric Jamieson, MD a Michel A. Marchand,
More informationAn Evaluation Study on the Quietness of the ATS Valve
Original Article An Evaluation Study on the Quietness of the ATS Valve Tomofumi Umeda, MD Background: The closure sound of the ATS bileaflet mechanical valve is said to be quieter than that of the other
More informationThe advantages and disadvantages of mechanical valve prostheses and
Surgery for Acquired Cardiovascular Disease Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients Ye-Ying Cen, MA Donald D. Glower, MD Kevin Landolfo,
More informationW. Schlick, M.D., J. Mlczoch, M.D., G. Kronik, M.D., and E. Wolner, M.D.
Implantation of the Durornedics Bileaflet Cardiac Valve Prosthesis in 400 Patients W. Klepetko, M.D., A. Moritz, M.D., G. KhunlBrady, M.D., W. Schreiner, Ph.D., W. Schlick, M.D., J. Mlczoch, M.D., G. Kronik,
More informationMitral valve replacement at Tygerberg Hospital: a 5 year follow-up
Mitral valve replacement Mitral valve replacement at Tygerberg Hospital: a 5 year follow-up B.J. Barnard *, P.J. le Roux # and H.W.J. van Wyk * * Division of Cardiothoracic Surgery, Tygerberg Hospital
More information